OOIR: Observatory of International Research

Papers

(The TQCC of New England Journal of Medicine is 35. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-07-01 to 2024-07-01.)

Article	Citations
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine	11435
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine	7843
Dexamethasone in Hospitalized Patients with Covid-19	6803
Remdesivir for the Treatment of Covid-19 — Final Report	5348
Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19	4245
Mental Health and the Covid-19 Pandemic	3005
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure	2908
Dapagliflozin in Patients with Chronic Kidney Disease	2724
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report	2605
Empagliflozin in Heart Failure with a Preserved Ejection Fraction	2338
Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant	2274
BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting	2139
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates	2075
Cytokine Storm	2009
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19	1975
Multisystem Inflammatory Syndrome in U.S. Children and Adolescents	1897
Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant	1717
Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination	1713
Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results	1704
Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer	1616
Once-Weekly Semaglutide in Adults with Overweight or Obesity	1590
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia	1469
Multiorgan and Renal Tropism of SARS-CoV-2	1466
Lecanemab in Early Alzheimer’s Disease	1464
New Creatinine- and Cystatin C–Based Equations to Estimate GFR without Race	1455

Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19	1451
Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months	1422
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19	1419
Genomewide Association Study of Severe Covid-19 with Respiratory Failure	1395
Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19	1303
Monkeypox Virus Infection in Humans across 16 Countries — April–June 2022	1289
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma	1279
Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19	1278
Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients	1276
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes	1227
Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer	1169
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults	1164
Early Rhythm-Control Therapy in Patients with Atrial Fibrillation	1154
Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure	1146
Covid-19 Breakthrough Infections in Vaccinated Health Care Workers	1138
Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination	1113
Severe Covid-19	1103
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months	1069
Colchicine in Patients with Chronic Coronary Disease	1067
Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host	1065
SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19	1065
KRAS^G12C Inhibition with Sotorasib in Advanced Solid Tumors	1050
Efficacy of Tocilizumab in Patients Hospitalized with Covid-19	1041
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19	1041
Multisystem Inflammatory Syndrome in Children in New York State	1039
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer	1028
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma	1028
Mild or Moderate Covid-19	1027
Osimertinib in ResectedEGFR-Mutated Non–Small-Cell Lung Cancer	1027
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma	1019
Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction	1017
Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant	1014
Hidden in Plain Sight — Reconsidering the Use of Race Correction in Clinical Algorithms	1002
CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia	1000
Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC	996
Tirzepatide Once Weekly for the Treatment of Obesity	996
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer	995
A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19	981
Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia	970
Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes	952
Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine	950
The Effect of Advances in Lung-Cancer Treatment on Population Mortality	934
A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis	925
Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine	923
Sotorasib for Lung Cancers with KRAS p.G12C Mutation	912
Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates	906
How Structural Racism Works — Racist Policies as a Root Cause of U.S. Racial Health Inequities	892
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer	891
Rapid Decay of Anti–SARS-CoV-2 Antibodies in Persons with Mild Covid-19	888
Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel	884

CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis	882
Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma	873
Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19	856
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma	844
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer	836
Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients	834
Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants	822
Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab	821
Waning Immunity after the BNT162b2 Vaccine in Israel	820
Reduced Rate of Hospital Admissions for ACS during Covid-19 Outbreak in Northern Italy	784
Saliva or Nasopharyngeal Swab Specimens for Detection of SARS-CoV-2	783
HPV Vaccination and the Risk of Invasive Cervical Cancer	778
Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine	775
Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19	773
Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination	765
Humoral Immune Response to SARS-CoV-2 in Iceland	763
Empagliflozin in Patients with Chronic Kidney Disease	760
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes	759
Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers	753
Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis	741
Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting	737
Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients	722
Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia	712
Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents	712
Donanemab in Early Alzheimer’s Disease	698
Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease	697
Trial of Psilocybin versus Escitalopram for Depression	694
Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19	692
Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults	691
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma	680
PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer	677
Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile	673
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer	672
A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia	670
Neuropathological Features of Covid-19	666
Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons	666
Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes	666
False Negative Tests for SARS-CoV-2 Infection — Challenges and Implications	660
Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar	658
Autophagy in Human Diseases	658
Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19	657
Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine	633
Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination	630
Somatic Mutations in UBA1 and Severe Adult-Onset Autoinflammatory Disease	622
Rethinking Covid-19 Test Sensitivity — A Strategy for Containment	618
Benefits, Limits, and Risks of GPT-4 as an AI Chatbot for Medicine	617
Vaccine Breakthrough Infections with SARS-CoV-2 Variants	613
First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer	611
Pathophysiology of Inflammatory Bowel Diseases	601
Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19	590
New-Onset Diabetes in Covid-19	579
Capmatinib inMETExon 14–Mutated orMET-Amplified Non–Small-Cell Lung Cancer	566
Racial Health Disparities and Covid-19 — Caution and Context	561
New SARS-CoV-2 Variants — Clinical, Public Health, and Vaccine Implications	557
Breast Cancer Risk Genes — Association Analysis in More than 113,000 Women	556
Racial Bias in Pulse Oximetry Measurement	555
Hypothermia versus Normothermia after Out-of-Hospital Cardiac Arrest	552
Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis	546
Acquired Resistance to KRAS^G12C Inhibition in Cancer	542
Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa	541
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer	540
Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma	536
Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19	532
Detection of SARS-CoV-2 with SHERLOCK One-Pot Testing	529
The Covid-19 Pandemic and the Incidence of Acute Myocardial Infarction	526
Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant	519
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer	518
Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer	517
Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations	511
Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines	509
Out-of-Hospital Cardiac Arrest during the Covid-19 Outbreak in Italy	507
Neutralizing Activity of BNT162b2-Elicited Serum	504
Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer	502
Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma	498
Avacopan for the Treatment of ANCA-Associated Vasculitis	498
Children with Covid-19 in Pediatric Emergency Departments in Italy	493
Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of Covid-19	492
Covid-19 — Implications for the Health Care System	488
Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease	482
Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma	481

Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection	480
Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine	476
Efficacy of Selpercatinib in RET-Altered Thyroid Cancers	471
Evidence of Artemisinin-Resistant Malaria in Africa	468
Myocarditis after Covid-19 Vaccination in a Large Health Care Organization	466
REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19	463
Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma	462
Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients	462
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer	460
Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel	452
Neutralization Escape by SARS-CoV-2 Omicron Subvariants BA.2.12.1, BA.4, and BA.5	448
Diffuse Large B-Cell Lymphoma	442
A Bivalent Omicron-Containing Booster Vaccine against Covid-19	441
Trastuzumab Deruxtecan in HER2 -Mutant Non–Small-Cell Lung Cancer	440
A Population-Based Study of Genes Previously Implicated in Breast Cancer	439
Evinacumab for Homozygous Familial Hypercholesterolemia	439
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma	438
Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer	437
Clinical Features of Vaccine-Induced Immune Thrombocytopenia and Thrombosis	430
Homologous and Heterologous Covid-19 Booster Vaccinations	429
Cryoablation or Drug Therapy for Initial Treatment of Atrial Fibrillation	427
Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age	422
Transmission of SARS-CoV-2 in Domestic Cats	420
Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma	419
Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants	418
Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19	417
Osteoarthritis of the Knee	413
Microvascular Injury in the Brains of Patients with Covid-19	411
Spectrum of Fibrotic Lung Diseases	408
Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase	407
Migraine	407
Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine	406
Structural Racism, Social Risk Factors, and Covid-19 — A Dangerous Convergence for Black Americans	404
Endovascular Therapy for Acute Stroke with a Large Ischemic Region	402
Race and Genetic Ancestry in Medicine — A Time for Reckoning with Racism	401
21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer	397
Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections	396
Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer	394
Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women	392
Teclistamab in Relapsed or Refractory Multiple Myeloma	392
Lupus Anticoagulant and Abnormal Coagulation Tests in Patients with Covid-19	391
Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer	390
Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure	390
Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants	388
SARS-CoV-2 Vaccine–Induced Immune Thrombotic Thrombocytopenia	385
Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines	381
Ofatumumab versus Teriflunomide in Multiple Sclerosis	380
Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes	376
SARS-CoV-2 Omicron Variant Neutralization in Serum from Vaccinated and Convalescent Persons	375
Endometrial Cancer	375
Phase 1–2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS	373
100,000 Genomes Pilot on Rare-Disease Diagnosis in Health Care — Preliminary Report	369
Trends in Diabetes Treatment and Control in U.S. Adults, 1999–2018	367
Protection against the Omicron Variant from Previous SARS-CoV-2 Infection	361
Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression	361
Collateral Effect of Covid-19 on Stroke Evaluation in the United States	360
Timing of Initiation of Renal-Replacement Therapy in Acute Kidney Injury	355
Cryoballoon Ablation as Initial Therapy for Atrial Fibrillation	354
Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection	353
Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings	352
Effect of Salt Substitution on Cardiovascular Events and Death	351
Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19	351
Left Atrial Appendage Occlusion during Cardiac Surgery to Prevent Stroke	349
SARS-CoV-2 Variants in Patients with Immunosuppression	347
Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia	347
Trial of Intensive Blood-Pressure Control in Older Patients with Hypertension	346
Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD	344
SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3	344
Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer	342
Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination	341
Shedding of Viable SARS-CoV-2 after Immunosuppressive Therapy for Cancer	341
Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA	340
Adagrasib in Non–Small-Cell Lung Cancer Harboring a KRAS ^G12C Mutation	339
Trial of Sodium Phenylbutyrate–Taurursodiol for Amyotrophic Lateral Sclerosis	334
Covid-19 in Immune-Mediated Inflammatory Diseases — Case Series from New York	333
Surgery or Endovascular Therapy for Chronic Limb-Threatening Ischemia	332
A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH	329
Endovascular Therapy for Stroke Due to Basilar-Artery Occlusion	328
Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma	327
A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19	325
Efficacy of a Fourth Dose of Covid-19 mRNA Vaccine against Omicron	324
Effect of Covid-19 Vaccination on Transmission of Alpha and Delta Variants	323
Hypothermic Machine Perfusion in Liver Transplantation — A Randomized Trial	323
Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease	322
Plasma Neutralization of the SARS-CoV-2 Omicron Variant	322
Wrong but Useful — What Covid-19 Epidemiologic Models Can and Cannot Tell Us	320
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes	319
Maintaining Safety with SARS-CoV-2 Vaccines	316
SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination	314
Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar	312
Efficacy of Antibodies and Antiviral Drugs against Covid-19 Omicron Variant	312
Bipolar Disorder	311
Genetically Modified Porcine-to-Human Cardiac Xenotransplantation	311
Efficacy of Wolbachia-Infected Mosquito Deployments for the Control of Dengue	311
SARS-CoV-2 Variants and Vaccines	310